Hassan Kobaissi, DPM
Podiatrist · Hacienda Heights, CANPI 1932209624
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.0%), royalties or licence payments and food and beverage — rather than concentrated in one kind of arrangement. Extremity Medical accounts for 69.7% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $28,857, more than ten times the $2,006 reported in 2019. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $198.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Extremity Medical$46K
- Lifenet Health$9K
- Smith+Nephew$4K
- Biotissue Holdings Inc.$3K
- Stryker$1K
- Organogenesis Inc.$847
- plus $3K from 23 others
What the payments were for
- Royalty or licence$24,70437%
- Consulting fees$27,25041%
- Travel & lodging$4,4247%
- Food & beverage$10,03015%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Extremity Medical | 31 | $46,297 |
| Lifenet Health | 17 | $8,701 |
| Smith+Nephew | 153 | $3,736 |
| Biotissue Holdings Inc. | 32 | $2,982 |
| Stryker | 15 | $1,222 |
| Organogenesis Inc. | 14 | $847 |
| Mimedx Group, Inc. | 9 | $492 |
| KCI USA, Inc. | 5 | $270 |
| Treace Medical Concepts, Inc. | 6 | $206 |
| AbbVie(2 entities) | 6 | $176 |
| Osiris Therapeutics Inc. | 10 | $168 |
| Acera Surgical, Inc. | 2 | $149 |
| Integra Lifesciences Corporation | 4 | $141 |
| Molnlycke Health Care US, LLC | 5 | $138 |
| Linvatec Corporation | 1 | $128 |
| Cardiovascular Systems Inc. | 2 | $119 |
| Crossroads Extremity Systems, LLC | 1 | $108 |
| Orpyx Medical Technologies US Inc. | 1 | $96 |
| Bioventus LLC | 3 | $92 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $62 |
| Amniox Medical, Inc. | 6 | $61 |
| Polynovo North America LLC | 1 | $60 |
| Paragon 28, Inc. | 2 | $37 |
| Nevro Corp. | 1 | $30 |
| Exact Sciences | 1 | $24 |
| GSK | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Reprise Biomedical, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omni ARCH$16,547
- TheraGenesis Wound Matrix$8,330
- EX-FIX$4,250
- NEOX$1,940
- CLARIX$1,940
- PROstep$859
- Stravix$697
- GRAFIX PL$573
- Grafix$239
- GrafixPL$239
- PREVENA$198
- V.A.C. VERAFLO$198
- V.A.C. VERAFLO CLEANSE CHOICE$198
- BioBrace 23mm$128
- NeoSpan$128
- IBS$128
- Restrata Wound Matrix$122
- COLLAGENASE SANTYL$122
- Grafix PL PRIME$120
- DALVANCE$120
How this compares
$66,409 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 13 | $15,195 |
| Ketoconazole | 88 | $945 |
| Gabapentin | 22 | $177 |
| Clindamycin Hcl | 16 | $128 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $94 |
| Mupirocin | 14 | $63 |
| Cephalexin | 13 | $61 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $52 |
| Tramadol Hcl | 12 | $25 |
| Omeprazole | 12 | $16 |
| Ciprofloxacin Hcl | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $3,736 | $15,19513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 721 podiatrist providers in California.
Other podiatrist in Hacienda Heights
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.